AG
CRBP icon

Artal Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Artal Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,333
Closed -$2.84M – 120
2017
Q4 		$2.84M Buy
13,333
+8,333
+167% +$1.78M 0.04% 89
2017
Q3 		$1.07M Sell
5,000
-3,333
-40% -$652K 0.02% 106
2017
Q2 		$1.57M Buy
+8,333
New +$1.63M 0.03% 99

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Artal Group's CRBP Position: Q1 2018 in Review

Artal Group sold out of Corbus Pharmaceuticals (CRBP) in Q1 2018, closing a stake of 13,333 shares — an estimated $2.84M sold.

Artal Group first reported a position in CRBP in Q2 2017 and held it in 3 quarters. The position peaked at $2.84M in Q4 2017. 81 funds tracked by Wall St. Rank hold CRBP as of Q1 2018.

  • Artal Group reported no remaining Corbus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Artal Group sold 13,333 Corbus Pharmaceuticals shares in Q1 2018, an estimated $2.84M.
  • Artal Group first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • Artal Group's Corbus Pharmaceuticals position peaked at $2.84M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.